vs
Aclaris Therapeutics, Inc.（ACRS）与安进（AMGN）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是Aclaris Therapeutics, Inc.的7618.5倍（$9.9B vs $1.3M）。安进净利率更高（13.5% vs -1528.6%，领先1542.1%）。安进同比增速更快（8.6% vs -85.9%）。安进自由现金流更多（$961.0M vs $-13.2M）。过去两年安进的营收复合增速更高（15.1% vs -26.5%）
Aclaris Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对免疫疾病、炎症性疾病和皮肤病的创新靶向疗法，核心管线覆盖斑秃、白癜风等未满足临床需求领域，致力于为全球相关患者提供新型治疗选择。
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
ACRS vs AMGN — 直观对比
营收规模更大
AMGN
是对方的7618.5倍
$1.3M
营收增速更快
AMGN
高出94.5%
-85.9%
净利率更高
AMGN
高出1542.1%
-1528.6%
自由现金流更多
AMGN
多$974.2M
$-13.2M
两年增速更快
AMGN
近两年复合增速
-26.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3M | $9.9B |
| 净利润 | $-19.8M | $1.3B |
| 毛利率 | 58.9% | 69.8% |
| 营业利润率 | -1755.5% | 27.6% |
| 净利率 | -1528.6% | 13.5% |
| 营收同比 | -85.9% | 8.6% |
| 净利润同比 | 79.5% | 112.6% |
| 每股收益（稀释后） | $-0.16 | $2.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACRSAMGN
| Q4 25 | $1.3M | $9.9B | ||
| Q3 25 | $3.3M | $9.6B | ||
| Q2 25 | $1.8M | $9.2B | ||
| Q1 25 | $1.5M | $8.1B | ||
| Q4 24 | $9.2M | $9.1B | ||
| Q3 24 | $4.3M | $8.5B | ||
| Q2 24 | $2.8M | $8.4B | ||
| Q1 24 | $2.4M | $7.4B |
净利润ACRSAMGN
| Q4 25 | $-19.8M | $1.3B | ||
| Q3 25 | $-14.6M | $3.2B | ||
| Q2 25 | $-15.4M | $1.4B | ||
| Q1 25 | $-15.1M | $1.7B | ||
| Q4 24 | $-96.6M | $627.0M | ||
| Q3 24 | $-7.6M | $2.8B | ||
| Q2 24 | $-11.0M | $746.0M | ||
| Q1 24 | $-16.9M | $-113.0M |
毛利率ACRSAMGN
| Q4 25 | 58.9% | 69.8% | ||
| Q3 25 | 83.7% | 67.8% | ||
| Q2 25 | 71.0% | 67.2% | ||
| Q1 25 | 65.2% | 63.6% | ||
| Q4 24 | 92.3% | 65.7% | ||
| Q3 24 | 85.0% | 61.1% | ||
| Q2 24 | 77.4% | 61.4% | ||
| Q1 24 | 66.3% | 57.0% |
营业利润率ACRSAMGN
| Q4 25 | -1755.5% | 27.6% | ||
| Q3 25 | -519.8% | 26.4% | ||
| Q2 25 | -1035.9% | 28.9% | ||
| Q1 25 | -1242.9% | 14.5% | ||
| Q4 24 | -1082.3% | 25.4% | ||
| Q3 24 | -240.9% | 24.1% | ||
| Q2 24 | -464.7% | 22.8% | ||
| Q1 24 | -789.4% | 13.3% |
净利率ACRSAMGN
| Q4 25 | -1528.6% | 13.5% | ||
| Q3 25 | -443.0% | 33.7% | ||
| Q2 25 | -868.3% | 15.6% | ||
| Q1 25 | -1036.8% | 21.2% | ||
| Q4 24 | -1048.3% | 6.9% | ||
| Q3 24 | -174.6% | 33.3% | ||
| Q2 24 | -397.2% | 8.9% | ||
| Q1 24 | -706.5% | -1.5% |
每股收益（稀释后）ACRSAMGN
| Q4 25 | $-0.16 | $2.45 | ||
| Q3 25 | $-0.12 | $5.93 | ||
| Q2 25 | $-0.13 | $2.65 | ||
| Q1 25 | $-0.12 | $3.20 | ||
| Q4 24 | $-1.21 | $1.17 | ||
| Q3 24 | $-0.11 | $5.22 | ||
| Q2 24 | $-0.15 | $1.38 | ||
| Q1 24 | $-0.24 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.0M | $9.1B |
| 总债务越低越好 | — | $54.6B |
| 股东权益账面价值 | $103.1M | $8.7B |
| 总资产 | $160.5M | $90.6B |
| 负债/权益比越低杠杆越低 | — | 6.31× |
8季度趋势，按日历期对齐
现金及短期投资ACRSAMGN
| Q4 25 | $20.0M | $9.1B | ||
| Q3 25 | $25.3M | $9.4B | ||
| Q2 25 | $25.4M | $8.0B | ||
| Q1 25 | $30.4M | $8.8B | ||
| Q4 24 | $24.6M | $12.0B | ||
| Q3 24 | $47.7M | $9.0B | ||
| Q2 24 | $22.8M | $9.3B | ||
| Q1 24 | $35.8M | $9.7B |
总债务ACRSAMGN
| Q4 25 | — | $54.6B | ||
| Q3 25 | — | $54.6B | ||
| Q2 25 | — | $56.2B | ||
| Q1 25 | — | $57.4B | ||
| Q4 24 | — | $60.1B | ||
| Q3 24 | — | $60.4B | ||
| Q2 24 | — | $62.6B | ||
| Q1 24 | — | $64.0B |
股东权益ACRSAMGN
| Q4 25 | $103.1M | $8.7B | ||
| Q3 25 | $120.1M | $9.6B | ||
| Q2 25 | $131.7M | $7.4B | ||
| Q1 25 | $144.1M | $6.2B | ||
| Q4 24 | $155.6M | $5.9B | ||
| Q3 24 | $130.2M | $7.5B | ||
| Q2 24 | $133.8M | $5.9B | ||
| Q1 24 | $142.0M | $5.0B |
总资产ACRSAMGN
| Q4 25 | $160.5M | $90.6B | ||
| Q3 25 | $175.5M | $90.1B | ||
| Q2 25 | $189.1M | $87.9B | ||
| Q1 25 | $198.1M | $89.4B | ||
| Q4 24 | $220.3M | $91.8B | ||
| Q3 24 | $182.4M | $90.9B | ||
| Q2 24 | $161.1M | $90.9B | ||
| Q1 24 | $174.1M | $93.0B |
负债/权益比ACRSAMGN
| Q4 25 | — | 6.31× | ||
| Q3 25 | — | 5.67× | ||
| Q2 25 | — | 7.57× | ||
| Q1 25 | — | 9.24× | ||
| Q4 24 | — | 10.23× | ||
| Q3 24 | — | 8.02× | ||
| Q2 24 | — | 10.57× | ||
| Q1 24 | — | 12.75× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-13.1M | $1.6B |
| 自由现金流经营现金流 - 资本支出 | $-13.2M | $961.0M |
| 自由现金流率自由现金流/营收 | -1015.8% | 9.7% |
| 资本支出强度资本支出/营收 | 1.9% | 6.5% |
| 现金转化率经营现金流/净利润 | — | 1.20× |
| 过去12个月自由现金流最近4个季度 | $-47.2M | $8.1B |
8季度趋势，按日历期对齐
经营现金流ACRSAMGN
| Q4 25 | $-13.1M | $1.6B | ||
| Q3 25 | $-10.9M | $4.7B | ||
| Q2 25 | $-10.0M | $2.3B | ||
| Q1 25 | $-13.1M | $1.4B | ||
| Q4 24 | $-8.9M | $4.8B | ||
| Q3 24 | $22.0M | $3.6B | ||
| Q2 24 | $-12.3M | $2.5B | ||
| Q1 24 | $-20.8M | $689.0M |
自由现金流ACRSAMGN
| Q4 25 | $-13.2M | $961.0M | ||
| Q3 25 | $-11.0M | $4.2B | ||
| Q2 25 | $-10.0M | $1.9B | ||
| Q1 25 | $-13.1M | $980.0M | ||
| Q4 24 | — | $4.4B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | $-12.3M | $2.2B | ||
| Q1 24 | $-20.9M | $459.0M |
自由现金流率ACRSAMGN
| Q4 25 | -1015.8% | 9.7% | ||
| Q3 25 | -332.1% | 44.4% | ||
| Q2 25 | -563.5% | 20.8% | ||
| Q1 25 | -900.3% | 12.0% | ||
| Q4 24 | — | 48.4% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | -446.0% | 26.5% | ||
| Q1 24 | -873.6% | 6.2% |
资本支出强度ACRSAMGN
| Q4 25 | 1.9% | 6.5% | ||
| Q3 25 | 0.7% | 4.6% | ||
| Q2 25 | 1.2% | 4.0% | ||
| Q1 25 | 3.0% | 5.0% | ||
| Q4 24 | 0.0% | 4.1% | ||
| Q3 24 | 0.0% | 3.0% | ||
| Q2 24 | 0.5% | 2.8% | ||
| Q1 24 | 5.6% | 3.1% |
现金转化率ACRSAMGN
| Q4 25 | — | 1.20× | ||
| Q3 25 | — | 1.46× | ||
| Q2 25 | — | 1.59× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 7.61× | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | 3.30× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACRS
暂无分部数据
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
